<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: operations", fill: "#ff007f"},
{source: "1: operations", target: "1: together with", fill: "#ff007f"},
{source: "1: together with", target: "1: risk factors set forth", fill: "#ff007f"},
{source: "1: operations", target: "3: uncertainties together with", fill: "#e6e6fa"},
{source: "3: uncertainties together with", target: "3: financial condition", fill: "#e6e6fa"},
{source: "3: financial condition", target: "3: operations cash flows strategies", fill: "#e6e6fa"},
{source: "3: operations cash flows strategies", target: "3: adverse manner", fill: "#e6e6fa"},
{source: "3: uncertainties together with", target: "11: United States ", fill: "#f88379"},
{source: "11: United States ", target: "11: provided through third parties with whom", fill: "#f88379"},
{source: "11: provided through third parties with whom", target: "11: marketing agreements", fill: "#f88379"},
{source: "11: United States ", target: "15: Substantial Reliance ", fill: "#014421"},
{source: "15: Substantial Reliance ", target: "15: total revenues", fill: "#014421"},
{source: "15: total revenues", target: "15: December ", fill: "#014421"},
{source: "15: Substantial Reliance ", target: "21: customers may continue", fill: "#ed1c24"},
{source: "21: customers may continue", target: "21: significant", fill: "#ed1c24"},
{source: "21: significant", target: "21: revenue during", fill: "#ed1c24"},
{source: "21: revenue during", target: "21: given period", fill: "#ed1c24"},
{source: "21: given period", target: "21: foreseeable future", fill: "#ed1c24"},
{source: "21: customers may continue", target: "22: Except ", fill: "#bc8f8f"},
{source: "22: Except ", target: "22: agreement", fill: "#bc8f8f"},
{source: "22: agreement", target: "22: no longterm purchase commitments", fill: "#bc8f8f"},
{source: "22: no longterm purchase commitments", target: "22: generally", fill: "#bc8f8f"},
{source: "22: generally", target: "22: transactions", fill: "#bc8f8f"},
{source: "22: Except ", target: "39: uncertainties associated with", fill: "#e2725b"},
{source: "39: uncertainties associated with", target: "39: market there", fill: "#e2725b"},
{source: "39: market there", target: "39: will continue", fill: "#e2725b"},
{source: "39: uncertainties associated with", target: "44: competitors", fill: "#e8000d"},
{source: "44: competitors", target: "44: manufacturers", fill: "#e8000d"},
{source: "44: manufacturers", target: "44: imaging equipment", fill: "#e8000d"},
{source: "44: competitors", target: "61: fluctuations", fill: "#a57164"},
{source: "61: fluctuations", target: "61: volatility", fill: "#a57164"},
{source: "61: volatility", target: "61: common stock", fill: "#a57164"},
{source: "61: fluctuations", target: "63: quarterly license", fill: "#d2b48c"},
{source: "63: quarterly license", target: "63: difficult", fill: "#d2b48c"},
{source: "63: difficult", target: "63: significant", fill: "#d2b48c"},
{source: "63: significant", target: "63: clients decisions", fill: "#d2b48c"},
{source: "63: clients decisions", target: "63: enter into license agreements with", fill: "#d2b48c"},
{source: "63: enter into license agreements with", target: "63: last few weeks", fill: "#d2b48c"},
{source: "63: last few weeks", target: "63: each quarter", fill: "#d2b48c"},
{source: "63: each quarter", target: "63: license transactions", fill: "#d2b48c"},
{source: "63: license transactions", target: "63: vary significantly", fill: "#d2b48c"},
{source: "63: vary significantly", target: "63: license fee revenue may likely", fill: "#d2b48c"},
{source: "63: license fee revenue may likely", target: "63: services revenue", fill: "#d2b48c"},
{source: "63: services revenue", target: "63: subsequent quarters", fill: "#d2b48c"},
{source: "63: subsequent quarters", target: "63: clients may unexpectedly postpone", fill: "#d2b48c"},
{source: "63: clients may unexpectedly postpone", target: "63: strategic priorities", fill: "#d2b48c"},
{source: "63: strategic priorities", target: "63: objectives budget", fill: "#d2b48c"},
{source: "63: objectives budget", target: "63: uncertainty", fill: "#d2b48c"},
{source: "63: uncertainty", target: "63: combinations", fill: "#d2b48c"},
{source: "63: combinations", target: "63: software industry may", fill: "#d2b48c"},
{source: "63: software industry may", target: "63: prospective clients", fill: "#d2b48c"},
{source: "63: prospective clients", target: "63: cancel postpone", fill: "#d2b48c"},
{source: "63: cancel postpone", target: "63: reduce capital spending", fill: "#d2b48c"},
{source: "63: reduce capital spending", target: "63: evaluations", fill: "#d2b48c"},
{source: "63: evaluations", target: "63: purchasing processes vary", fill: "#d2b48c"},
{source: "63: purchasing processes vary", target: "63: significantly from company", fill: "#d2b48c"},
{source: "63: significantly from company", target: "63: clients internal approval", fill: "#d2b48c"},
{source: "63: clients internal approval", target: "63: expenditure authorization process", fill: "#d2b48c"},
{source: "63: expenditure authorization process", target: "63: software product", fill: "#d2b48c"},
{source: "63: software product", target: "63: enhancements", fill: "#d2b48c"},
{source: "63: enhancements", target: "63: new software product announcements", fill: "#d2b48c"},
{source: "63: new software product announcements", target: "63: existing clients may decline", fill: "#d2b48c"},
{source: "63: existing clients may decline", target: "63: renew support", fill: "#d2b48c"},
{source: "63: renew support", target: "63: market pressures may limit", fill: "#d2b48c"},
{source: "63: market pressures may limit", target: "63: increase support", fill: "#d2b48c"},
{source: "63: increase support", target: "63: upgrade from older versions", fill: "#d2b48c"},
{source: "63: upgrade from older versions", target: "63: prospective clients may decline", fill: "#d2b48c"},
{source: "63: prospective clients may decline", target: "63: new products", fill: "#d2b48c"},
{source: "63: new products", target: "63: sufficient client references", fill: "#d2b48c"},
{source: "63: sufficient client references", target: "63: defer revenues under", fill: "#d2b48c"},
{source: "63: defer revenues under", target: "63: recognition policies", fill: "#d2b48c"},
{source: "63: quarterly license", target: "69: grant clearance with respect", fill: "#b31b1b"},
{source: "69: grant clearance with respect", target: "69: enhancements", fill: "#b31b1b"},
{source: "69: enhancements", target: "69: review may involve", fill: "#b31b1b"},
{source: "69: review may involve", target: "69: could adversely affect", fill: "#b31b1b"},
{source: "69: could adversely affect", target: "69: market such future", fill: "#b31b1b"},
{source: "69: grant clearance with respect", target: "81: health care", fill: "#f0fff0"},
{source: "81: health care", target: "81: clearinghouses", fill: "#f0fff0"},
{source: "81: clearinghouses", target: "81: certain health care providers", fill: "#f0fff0"},
{source: "81: health care", target: "88: filed patent applications with", fill: "#fe2712"},
{source: "88: filed patent applications with", target: "88: certain aspects", fill: "#fe2712"},
{source: "88: certain aspects", target: "88: technology", fill: "#fe2712"},
{source: "88: technology", target: "88: generally", fill: "#fe2712"},
{source: "88: generally", target: "88: patent protection with respect", fill: "#fe2712"},
{source: "88: patent protection with respect", target: "88: technologies", fill: "#fe2712"},
{source: "88: filed patent applications with", target: "START_HERE", fill: "#fe2712"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Disapprove</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-disclosure_agreement">Non-disclosure agreement</a></td>
      <td>A non-disclosure agreement (NDA), also known as a confidentiality agreement (CA), confidential disclosure agreement (CDA), proprietary information agreement (PIA), secrecy agreement (SA), or non-disparagement agreement, is a legal contract or part of a contract between at least two parties that outlines confidential material, knowledge, or information that the parties wish to share with one another for certain purposes, but wish to restrict access to. Doctor–patient confidentiality (physician–patient privilege), attorney–client privilege, priest–penitent privilege and bank–client confidentiality agreements are examples of NDAs, which are often not enshrined in a written contract between the parties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_7">December 7</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_22">December 22</a></td>
      <td>December 22 is the 356th day of the year (357th in leap years) in the Gregorian calendar; nine days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\nAD 69 – Vespasian is proclaimed Emperor of Rome; his predecessor, Vitellius, attempts to abdicate but is captured and killed at the Gemonian stairs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Good_Friday_Agreement">Good Friday Agreement</a></td>
      <td>The Good Friday Agreement (GFA), or Belfast Agreement (Irish: Comhaontú Aoine an Chéasta or Comhaontú Bhéal Feirste; Ulster-Scots: Guid Friday Greeance or Bilfawst Greeance), is a pair of agreements signed on 10 April 1998 that ended most of the violence of the Troubles, a political conflict in Northern Ireland that had ensued since the late 1960s. It was a major development in the Northern Ireland peace process of the 1990s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenuptial_agreement">Prenuptial agreement</a></td>
      <td>A prenuptial agreement, antenuptial agreement, or premarital agreement (commonly referred to as a prenup), is a written contract entered into by a couple prior to marriage or a civil union that enables them to select and control many of the legal rights they acquire upon marrying, and what happens when their marriage eventually ends by death or divorce. Couples enter into a written prenuptial agreement to supersede many of the default marital laws that would otherwise apply in the event of divorce, such as the laws that govern the division of property, retirement benefits, savings, and the right to seek alimony (spousal support) with agreed-upon terms that provide certainty and clarify their marital rights.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Credit_rating">Credit rating</a></td>
      <td>A credit rating is an evaluation of the credit risk of a prospective debtor (an individual, a business, company or a government), predicting their ability to pay back the debt, and  an implicit forecast of the likelihood of the debtor defaulting.\nThe credit rating represents an evaluation of a credit rating agency of the qualitative and quantitative information for the prospective debtor, including information provided by the prospective debtor and other non-public information obtained by the credit rating agency's analysts.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_testing">Design for testing</a></td>
      <td>Design for testing or design for testability (DFT) consists of  IC design techniques that add testability features to a hardware product design. The added features make it easier to develop and apply manufacturing tests to the designed hardware.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tivoization">Tivoization</a></td>
      <td>Tivoization  is the practice of designing hardware that incorporates software under the terms of a copyleft software license like the GNU General Public License (GNU GPL), but uses hardware restrictions or digital rights management (DRM) to prevent users from running modified versions of the software on that hardware. Richard Stallman coined the term in reference to TiVo's use of GNU GPL licensed software on the TiVo brand digital video recorders (DVR), which actively blocks users from running modified software on its hardware by design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/High_Desert_State_Prison_(California)">High Desert State Prison (California)</a></td>
      <td>High Desert State Prison (HDSP) is a high-security state prison that houses level IV inmates located in Leavitt, Lassen County, California. Opened in 1995, it has a capacity of 2,324 persons.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Universal_health_care">Universal health care</a></td>
      <td>Universal health care (also called universal health coverage, universal coverage, or universal care) is a health care system in which all residents of a particular country or region are assured access to health care. It is generally organized around providing either all residents or only those who cannot afford on their own, with either health services or the means to acquire them, with the end goal of improving health outcomes.Universal healthcare does not imply coverage for all cases and for all people – only that all people have access to healthcare when and where needed without financial hardship.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>VITAL IMAGES INC      Item 1A    Risk Factors         Discussion of our business and <font color="blue">operations</font> included in this annual report on     Form 10-K should be read <font color="blue">together with</font> the <font color="blue">risk factors set forth</font> below</td>
    </tr>
    <tr>
      <td>They <font color="blue">describe various risks</font> and <font color="blue">uncertainties</font> to which we are, or may become     subject</td>
    </tr>
    <tr>
      <td>These  risks  and <font color="blue">uncertainties</font>, <font color="blue">together with</font> other factors     described  elsewhere  in this report, have the potential to affect our     business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font>, cash flows, strategies     or prospects in a material and <font color="blue">adverse manner</font></td>
    </tr>
    <tr>
      <td>New risks may emerge at any     time, and we <font color="blue">cannot predict</font> those risks or estimate the extent to which they     <font color="blue">may affect financial performance</font></td>
    </tr>
    <tr>
      <td>Each of the <font color="blue">risks described</font> below could     <font color="blue"><font color="blue">adversely</font> impact</font> the value of our securities</td>
    </tr>
    <tr>
      <td>These statements, like all     statements in this report, speak only as of the date of this report (unless     another date is indicated), and we undertake <font color="blue">no obligation</font> to update or     revise the statements in light of <font color="blue">future <font color="blue">development</font>s</font></td>
    </tr>
    <tr>
      <td>Market Acceptance         Our <font color="blue">success depends on</font> our ability to continue to <font color="blue"><font color="blue">successfully</font> market</font> <font color="blue">Vitrea     </font>and  ViTALConnect  software  for  <font color="blue">clinical use</font>, and on the ability and     <font color="blue">willingness</font> of physicians to use enterprise-wide advanced <font color="blue">visualization</font>     <font color="blue">software medical imaging software</font> in <font color="blue">clinical analysis</font> and therapy planning</td>
    </tr>
    <tr>
      <td>The enterprise-wide advanced <font color="blue">visualization</font> software offered by Vitrea and     ViTALConnect are <font color="blue">alternatives</font> to the <font color="blue">conventional methods traditionally used</font>     for viewing <font color="blue">medical images</font> in the <font color="blue">clinical setting</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">acceptance</font> of <font color="blue">Vitrea     </font>and ViTALConnect <font color="blue">by physicians</font> and other <font color="blue">clinicians will depend on</font> our     ability  to educate those users as to the speed, ease-of-use and other     <font color="blue">benefits offered by</font> the Vitrea and ViTALConnect systems, as well as our     <font color="blue">timely introduction</font> of new features and functions</td>
    </tr>
    <tr>
      <td>There can be no assurance     that  users  will  <font color="blue">prefer advanced <font color="blue">visualization</font></font> and <font color="blue">analysis software</font>     solutions over less expensive two-dimensional medical imaging software or     that we will succeed in our efforts to further develop, <font color="blue">commercialize</font>, and     achieve market <font color="blue">acceptance</font> for Vitrea and ViTALConnect or for any other     product in the <font color="blue">clinical setting</font></td>
    </tr>
    <tr>
      <td>Further, all of our business in markets     outside the <font color="blue">United States </font>is <font color="blue">provided through <font color="blue">third parties</font> with whom</font> we     have  <font color="blue">marketing <font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that these third     <font color="blue">parties will</font> wish to continue our <font color="blue"><font color="blue">relationships</font> on</font> an <font color="blue">indefinite basis</font> or     under  the <font color="blue">same terms as</font> the business is <font color="blue">currently conducted</font></td>
    </tr>
    <tr>
      <td>Further,     although we plan to develop <font color="blue">direct <font color="blue">relationships</font> with customers</font> in markets     outside  the  United States, there can be no assurance that we will be     successful in doing so</td>
    </tr>
    <tr>
      <td>The loss of or adverse changes in our <font color="blue">relationships</font>     with our <font color="blue">third party</font> business partners, and our failure to <font color="blue">establish direct</font>     <font color="blue">relationships</font>  with  <font color="blue">customers outside</font> the United States, would have a     material <font color="blue">adverse impact on</font> our business, <font color="blue">financial condition</font>, and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantial Reliance </font>on a Single Product         Revenue related to Vitrea constituted 95prca of our <font color="blue"><font color="blue">total revenue</font>s</font> for the year     ended  <font color="blue">December </font>31, 2005, 96prca of our <font color="blue"><font color="blue">total revenue</font>s</font> for the year ended     <font color="blue">December </font>31,  2004,  and  98prca of our <font color="blue"><font color="blue">total revenue</font>s</font> for the year ended     <font color="blue">December </font>31, 2003</td>
    </tr>
    <tr>
      <td>We anticipate that revenue from the sale of Vitrea will     continue  to  account for a substantial portion of our revenue for the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>As such, if Vitrea became disfavored <font color="blue">by physicians</font>, it     would have a material <font color="blue">adverse impact on</font> our business, <font color="blue">financial condition</font>,     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font>on Major Customers         One of our principal <font color="blue">distribution</font> channels is to sell our Vitrea medical     imaging  software in <font color="blue"><font color="blue">connection with</font> medical <font color="blue">imaging equipment</font> sold by</font>     Toshiba</td>
    </tr>
    <tr>
      <td><font color="blue">Sales to Toshiba </font>accounted for 47prca of our <font color="blue">total revenue</font> for the     year ended <font color="blue">December </font>31, 2005, 50prca of our <font color="blue">total revenue</font> for the year ended     <font color="blue">December </font>31,  2004,  and  42prca  of our <font color="blue">total revenue</font> for the year ended     <font color="blue">December </font>31, 2003</td>
    </tr>
    <tr>
      <td>Toshiba’s account receivable represented 36prca of the     Company’s <font color="blue">accounts receivable at</font> <font color="blue">December </font>31, 2005 and 23prca at <font color="blue">December </font>31,     2004</td>
    </tr>
    <tr>
      <td>A limited number of large <font color="blue">customers <font color="blue">may continue</font></font> to account for a     <font color="blue">significant</font> portion                                           14     ______________________________________________________________________         of our <font color="blue">revenue during</font> any <font color="blue">given period</font> for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td><font color="blue">Except     </font>for our <font color="blue">agreement</font> with Toshiba, we have no long-term purchase <font color="blue">commitment</font>s     from any of our customers or business partners, and we <font color="blue">generally</font> make sales     pursuant to individual <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>Although our <font color="blue">agreement</font> with Toshiba has     been extended by amendment three times, most recently through <font color="blue">December </font>31,     2006, we can <font color="blue">provide no assurance</font> that our <font color="blue">agreement</font> with Toshiba will be     <font color="blue">extended beyond</font> <font color="blue">December </font>31, 2006</td>
    </tr>
    <tr>
      <td>A reduction, delay, or <font color="blue">cancellation</font> of     <font color="blue">orders from one</font> or more of our <font color="blue">significant</font> customers, or our <font color="blue">inability</font> to     collect  <font color="blue">accounts receivable from</font> these customers, likely would have a     material adverse effect on our <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td>Impact of Purchase Commitments to Third Parties         As part of our business, we may offer <font color="blue">third party</font> products as components     within our products or <font color="blue">as optional modules</font> to our products</td>
    </tr>
    <tr>
      <td>As a condition     of entering into these <font color="blue">agreement</font>s, or for other business reasons, the third     <font color="blue">parties may</font> require us to commit to purchase a <font color="blue">certain volume</font> of their     products, irrespective of the amount of their products that we sell to our     customers</td>
    </tr>
    <tr>
      <td>If we <font color="blue"><font color="blue">enter into</font> such</font> a <font color="blue">volume <font color="blue">commitment</font> with</font> a <font color="blue">third party</font> but     do not sell a <font color="blue">sufficient volume</font> of its products, then we may be required to     pay the <font color="blue">third party</font> directly for the deficit in sales</td>
    </tr>
    <tr>
      <td>We incurred such an     event  during  the  <font color="blue">fourth quarter</font> of 2005, in which we did not sell a     <font color="blue">sufficient volume</font> of our partner R2 Technology, Inc</td>
    </tr>
    <tr>
      <td>’s (“R2”) lung nodule     computer-aided-diagnosis <font color="blue">software product</font> to meet our <font color="blue">quarterly purchase</font>     <font color="blue"><font color="blue">commitment</font> under</font> our <font color="blue">contract with</font> R2, resulting in a loss of <font color="blue">approximately</font>     dlra410cmam000 in the <font color="blue">fourth quarter</font> of 2005</td>
    </tr>
    <tr>
      <td>There can be no assurance that we     will not have similar deficits in <font color="blue">future quarters under <font color="blue">commitment</font>s</font> we     may have made to R2 or other providers of <font color="blue">third party</font> products</td>
    </tr>
    <tr>
      <td>Regarding     R2, our <font color="blue">commitment</font> is for <font color="blue">approximately</font> dlra414cmam000 per <font color="blue">quarter through</font> the     quarter ended March 31, 2006</td>
    </tr>
    <tr>
      <td>The contractual <font color="blue">commitment</font>s continue through     the quarter ended June 30, 2008, but they may be <font color="blue">reduced during <font color="blue">each quarter</font></font>     after the quarter ended March 31, 2006 to the lowest of: (i) the quarterly     <font color="blue">commitment</font> in the preceding quarter; (ii) the quarterly <font color="blue">commitment</font> of the     <font color="blue">preceding quarter multiplied by</font> the <font color="blue">percent by which</font> the R2 Lung CAD product     revenue  in  the <font color="blue">preceding quarter fell</font> below that quarter’s quarterly     <font color="blue">commitment</font>,  up to a <font color="blue">maximum decline</font> of twenty-three percent (23prca); or     (iii) two times the R2 Lung CAD <font color="blue">product revenue generated by</font> R2 during the     preceding  <font color="blue">quarter through</font> all other sales, marketing and <font color="blue">distribution</font>     channels,  excluding R2 Lung CAD <font color="blue">product revenue generated through</font> the     <font color="blue">agreement</font> with us; provided, that if at any time during the remainder of the     <font color="blue">agreement</font> the quarterly <font color="blue">commitment</font> is less than dlra414cmam000 and R2 Lung CAD     Product revenue for a quarter exceeds dlra414cmam000, our quarterly <font color="blue">commitment</font> for     the <font color="blue">next quarter will again</font> be dlra414cmam000, and the quarterly <font color="blue">commitment</font> for     the  following  <font color="blue">quarters may again</font> be subject to the above <font color="blue">adjustment</font></td>
    </tr>
    <tr>
      <td>Additionally, at the end of every <font color="blue">fourth quarter</font> under the R2 <font color="blue">agreement</font>, if     the <font color="blue">aggregate revenue generated under</font> the <font color="blue">agreement</font> in the <font color="blue">previous four</font>     quarters exceeded dlra1cmam665cmam000, the remaining quarterly <font color="blue">commitment</font>s shall be     <font color="blue">reduced by</font> the amount of <font color="blue">excess divided by</font> the number of <font color="blue">quarters remaining</font>     under  the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, the <font color="blue">remaining potential</font>     aggregate <font color="blue">Applicable Minimums </font><font color="blue">range from</font> a minimum of <font color="blue">approximately</font> dlra414cmam000     to a maximum of <font color="blue">approximately</font> dlra4dtta1 million</td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font>on Market Growth          The enterprise-wide advanced <font color="blue">visualization</font> industry in which we market our     products  is still developing due to the <font color="blue">fairly recent availability</font> of     high-resolution  CT, MR and combined CT-PET scanners, high-performance     <font color="blue">computers at reduced prices</font>, the <font color="blue">recent adoption</font> of <font color="blue">industry standards</font> for     the  <font color="blue">generation</font>, <font color="blue">transmission</font> and storage of <font color="blue">medical imaging data</font>, and     changing <font color="blue">medical practices</font></td>
    </tr>
    <tr>
      <td>Historically, there has been a <font color="blue">perception</font> that     enterprise-wide advanced <font color="blue">visualization</font> was too slow, unresolved or <font color="blue">difficult</font>     for <font color="blue">clinical use</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">perception</font> was <font color="blue">due largely</font> to the <font color="blue">relatively slower</font>     processing  speed  of <font color="blue">available workstations</font> and the reality that true     <font color="blue">volumetric <font color="blue">acquisition</font></font> was not <font color="blue">previously available</font></td>
    </tr>
    <tr>
      <td>We believe that the     <font color="blue">recent advances</font> in <font color="blue">scanner <font color="blue">acquisition</font> resolution</font>, the <font color="blue">affordability</font> of     high-performance computers and the <font color="blue">development</font> of <font color="blue">industry standards</font> for the     <font color="blue">generation</font>,  <font color="blue">transmission</font>,  and  storage  of <font color="blue">imaging data will provide</font>     <font color="blue">opportunities</font> for substantial growth in the <font color="blue">medical software industry</font></td>
    </tr>
    <tr>
      <td>However, given the <font color="blue">uncertainties</font> associated with the developing stage of     this market, there can be no assurance that it <font color="blue">will continue</font> to develop in     the manner we anticipate</td>
    </tr>
    <tr>
      <td>Accordingly, there can be no assurance that the     enterprise-wide  advanced  <font color="blue">visualization</font>  <font color="blue">industry will provide growth</font>     <font color="blue">opportunities</font>  for  us  and our <font color="blue"><font color="blue">software product</font>s</font> or that our business     strategies  will  be  successful  as the <font color="blue">industry continues</font> to evolve</td>
    </tr>
    <tr>
      <td>Ultimately, if the enterprise-wide advanced <font color="blue">visualization</font> industry fails to     develop as we expect, our business, results of <font color="blue">operations</font> and financial     <font color="blue">condition will</font> be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Highly Competitive Industry         We <font color="blue">face intense <font color="blue">competition</font></font> in the enterprise-wide advanced <font color="blue">visualization</font>     industry</td>
    </tr>
    <tr>
      <td>We expect <font color="blue">technology</font> to continue to develop rapidly, and our     success  will  depend  to  a large extent on our ability to maintain a     <font color="blue">competitive</font>  position  with  our  products</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">competitors</font>  in  the     enterprise-wide advanced <font color="blue">visualization</font> industry include large, established     <font color="blue"><font color="blue">manufacture</font>rs</font>  of  CT  and  MR <font color="blue">imaging equipment</font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>such as GE     Healthcare,  Siemens Medical Systems, Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">Philips Medical Systems     </font><font color="blue">typically offer</font> their own enterprise-wide advanced <font color="blue">visualization</font> software     and <font color="blue">workstations as</font> part of their <font color="blue">integrated imaging</font> and <font color="blue">scanner systems</font></td>
    </tr>
    <tr>
      <td>Our software works on the <font color="blue">products offered by each</font> of these companies</td>
    </tr>
    <tr>
      <td>To     win business                                           15     ______________________________________________________________________         against equipment <font color="blue"><font color="blue">manufacture</font>rs</font>, we <font color="blue">must convince customers</font> to buy our     <font color="blue">software solutions separately from</font> their purchase of <font color="blue">imaging equipment</font>     instead of <font color="blue">buying integrated systems from</font> our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>In addition to having a <font color="blue">competitive</font> advantage in marketing enterprise-wide     advanced  <font color="blue">visualization</font>  tools  as an integrated part of their imaging     products, our <font color="blue">competitors</font> have <font color="blue">significant</font>ly <font color="blue">greater capital</font> and staffing     resources for research and <font color="blue">development</font> that are critical to success in the     dynamic enterprise-wide advanced <font color="blue">visualization</font> industry, more <font color="blue">recognizable</font>     brand names, and more well-established marketing and <font color="blue">distribution</font> networks</td>
    </tr>
    <tr>
      <td>Although price has been less <font color="blue">significant</font> than other factors, increasing     <font color="blue">competition</font>  may result in <font color="blue">price reductions</font> and reduced gross margins</td>
    </tr>
    <tr>
      <td>Additionally, we face <font color="blue">competition</font> from other entities, such as PACS vendors     and <font color="blue">developers</font> of <font color="blue">competitive</font> or <font color="blue">ancillary software packages</font></td>
    </tr>
    <tr>
      <td>We may not be     able to <font color="blue">compete <font color="blue">effective</font>ly</font> with such <font color="blue"><font color="blue">manufacture</font>rs</font> or <font color="blue">competing entities</font></td>
    </tr>
    <tr>
      <td>Risk of Technological Obsolescence         The enterprise-wide advanced <font color="blue">visualization</font> market is <font color="blue">characterized by rapid</font>     innovation and <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">compete <font color="blue">effective</font>ly</font>     in the marketplace, and products developed by our <font color="blue">competitors</font> may render our     <font color="blue">products obsolete</font> or non-<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Similarly, our <font color="blue">competitors</font> may succeed     in developing or <font color="blue">marketing products</font> that are viewed as providing superior     clinical  performance or are <font color="blue">less expensive than</font> our current or future     products</td>
    </tr>
    <tr>
      <td>Sarbanes-Oxley Compliance         Under Section 404 of the Sarbanes-Oxley Act of 2002, we are required to     evaluate and determine the <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue">internal controls</font> over     financial reporting</td>
    </tr>
    <tr>
      <td>We have dedicated a <font color="blue">significant</font> amount of time and     resources to <font color="blue">ensure <font color="blue">compliance with</font></font> this <font color="blue">legislation</font> for the year ended     <font color="blue">December </font>31, 2005 and <font color="blue">will continue</font> to do so for <font color="blue">future fiscal periods</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">may encounter problems</font> or delays in completing the review and <font color="blue">evaluation</font>,     the  <font color="blue">implementation</font>  of  <font color="blue">improvements</font>  and  the  receipt of a positive     <font color="blue">attestation</font>, or any <font color="blue">attestation</font> at all, from our <font color="blue">independent registered</font>     <font color="blue">public accounting firm</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">assessment</font> of our <font color="blue">internal controls</font>     may identify <font color="blue">deficiencies</font> that need to be addressed in our <font color="blue">internal controls</font>     over  financial reporting or other matters that <font color="blue">may raise concerns</font> for     investors and <font color="blue">therefore <font color="blue">adversely</font> affect</font> our stock price</td>
    </tr>
    <tr>
      <td>Fluctuations in Operating Results         We may experience <font color="blue">significant</font> <font color="blue">fluctuations</font> in <font color="blue">future annual</font> and quarterly     operating  results</td>
    </tr>
    <tr>
      <td>If  these  <font color="blue">fluctuations</font> occur, they may result in     <font color="blue">volatility</font> in the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Quarterly </font>revenue and operating     results <font color="blue">may fluctuate as</font> a result of a variety of factors that are outside     of our control including, but not limited to, the timing of <font color="blue">significant</font>     orders, the timing of <font color="blue">product <font color="blue">enhancements</font></font> and <font color="blue">new product introductions by</font>     us or our <font color="blue">competitors</font>, the pricing of our products, changes in customers’     budgets, and <font color="blue">competitive</font> conditions</td>
    </tr>
    <tr>
      <td>Our <font color="blue">quarterly license</font> and services     revenue may fluctuate and may be <font color="blue">difficult</font> to forecast for a variety of     reasons, including the following:         •                  a <font color="blue">significant</font> number of our existing and prospective     clients’ decisions regarding whether to <font color="blue">enter into</font> license <font color="blue">agreement</font>s with     us are made within the <font color="blue">last few weeks</font> or days of <font color="blue">each quarter</font>;       •                  the size of license <font color="blue">transactions</font> can vary <font color="blue">significant</font>ly;       •                  a decrease in <font color="blue">license fee revenue may likely</font> result in a     decrease in <font color="blue">services revenue</font> in the same or <font color="blue">subsequent quarters</font>;       •                  <font color="blue">clients may unexpectedly postpone</font> or cancel projects due     to changes in their <font color="blue">strategic priorities</font>, project objectives, budget or     personnel;       •                  the <font color="blue">uncertainty</font> caused by potential business <font color="blue"><font color="blue">combination</font>s</font>     in  the <font color="blue">software industry may</font> cause clients and <font color="blue">prospective clients</font> to     cancel, postpone or <font color="blue">reduce capital spending</font> projects on software;       •                   client  <font color="blue">evaluation</font>s  and <font color="blue">purchasing processes vary</font>     <font color="blue">significant</font>ly from company to company, and a client’s internal approval and     <font color="blue">expenditure authorization process</font> can be <font color="blue">difficult</font> and time consuming to     complete, even after selection of a vendor;       •                  the number, timing and significance of <font color="blue">software product</font>     <font color="blue">enhancements</font> and new <font color="blue">software product</font> announcements;       •                  <font color="blue">existing clients may decline</font> to <font color="blue">renew support</font> for our     products, and <font color="blue">market pressures may limit</font> our ability to <font color="blue">increase support</font>     fees or require clients to <font color="blue">upgrade from older versions</font> of our products;       •                  <font color="blue">prospective clients</font> may decline or defer the purchase of     <font color="blue">new products</font> or releases if we do not have <font color="blue">sufficient client references</font> for     those products; or       •                   we  may have  to  <font color="blue">defer revenues under</font> our revenue     <font color="blue">recognition policies</font></td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________         Government Regulation          Our products are subject to <font color="blue">regulation by</font> the FDA and by comparable agencies     in  foreign  countries</td>
    </tr>
    <tr>
      <td>In  the  United States, the FDA regulates the     <font color="blue">development</font>,  introduction, manufacturing, labeling and record keeping     procedures for <font color="blue">medical devices</font>, including 3D medical imaging software and     systems</td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue">marketing clearance from</font> the FDA for new     products and new <font color="blue">applications</font> for existing products can be time-consuming     and expensive</td>
    </tr>
    <tr>
      <td>Vitrea 2 and     ViTALConnect and our add-on options have been cleared to be marketed for use     with CT, MR and PET scanners</td>
    </tr>
    <tr>
      <td>The FDA may not <font color="blue">grant clearance with respect</font>     to our <font color="blue">future products</font> or <font color="blue">enhancements</font>, or future FDA <font color="blue">review may involve</font>     delays  that  <font color="blue">could <font color="blue">adversely</font> affect</font> our ability to <font color="blue">market such future</font>     products or <font color="blue">enhancements</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">future products</font> or <font color="blue">enhancements</font>     may be subject to a more lengthy and expensive pre-market approval process     with the FDA         Even if we obtain <font color="blue"><font color="blue">regulatory</font> <font color="blue">clearances</font></font> and approvals to market a product     from the FDA, these <font color="blue">approvals may entail limitations on</font> the <font color="blue">indicated uses</font>     of the product</td>
    </tr>
    <tr>
      <td>Product <font color="blue">clearances</font> and <font color="blue">approvals by</font> the FDA can also be     withdrawn  due  to  failure to <font color="blue"><font color="blue">comply with</font> <font color="blue">regulatory</font> standards</font> or the     occurrence of <font color="blue">unforeseen problems following initial approval</font></td>
    </tr>
    <tr>
      <td>The FDA could     <font color="blue">also limit</font> or prevent the <font color="blue">distribution</font> of our products and has the power to     require the recall of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>FDA <font color="blue"><font color="blue">regulations</font> depend heavily on</font>     <font color="blue">administrative interpretation</font>, and <font color="blue">future interpretations</font> made by the FDA or     other <font color="blue">regulatory</font> bodies may <font color="blue">adversely</font> affect us</td>
    </tr>
    <tr>
      <td>The FDA may inspect our     <font color="blue">facilities</font> and <font color="blue">operations</font> to determine whether we are in <font color="blue">compliance with</font>     <font color="blue">various <font color="blue">regulations</font></font> relating to specification, <font color="blue">development</font>, documentation,     <font color="blue">validation</font>,  testing, quality control and <font color="blue">product labeling</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA     </font>determines that we are in violation of <font color="blue">such <font color="blue">regulations</font></font>, it <font color="blue">could impose</font>     <font color="blue">civil penalties</font>, including fines, recall or <font color="blue">seize products</font> and, in extreme     cases, impose criminal sanctions</td>
    </tr>
    <tr>
      <td>We market our <font color="blue">products both domestically</font> and <font color="blue">internationally</font></td>
    </tr>
    <tr>
      <td><font color="blue">International     </font><font color="blue">regulatory</font> bodies have <font color="blue">established <font color="blue">varying <font color="blue">regulations</font></font> governing product</font>     standards,   packaging  <font color="blue">requirements</font>,  labeling  <font color="blue">requirements</font>,  import     restrictions, tariff <font color="blue">regulations</font>, duties and tax <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font>     or failure to <font color="blue">comply with</font> the <font color="blue">varying <font color="blue">regulations</font></font>, or the imposition of new     <font color="blue">regulations</font>, could restrict our ability to sell our products <font color="blue">internationally</font>     and <font color="blue">could <font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>Health Insurance Portability and Accountability Act of 1996 (“HIPAA”)         The HIPAA <font color="blue">regulations</font> are causing our customers to request that we sign     “business associate” <font color="blue">agreement</font>s with them</td>
    </tr>
    <tr>
      <td>A “business associate” is a     person or entity that performs <font color="blue">certain functions</font> or <font color="blue">activities</font> that involve     the use or <font color="blue">disclosure</font> of <font color="blue">protected health</font> information on behalf of, or that     provides  services  to,  a  covered  entity</td>
    </tr>
    <tr>
      <td>By law, the HIPAA Privacy     Rule applies  only  to  covered  entities  – health plans, <font color="blue">health care</font>     <font color="blue">clearinghouses</font>, and certain <font color="blue">health care</font> providers</td>
    </tr>
    <tr>
      <td>However, most <font color="blue">health care</font>     providers do not carry out all of their <font color="blue">health care</font> <font color="blue">activities</font> and functions     <font color="blue">by themselves</font></td>
    </tr>
    <tr>
      <td>Instead, they often use the services of a variety of other     persons or <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Privacy Rule </font><font color="blue">allows covered providers</font> and health     plans  to  disclose  protected  health  information to these “business     <font color="blue">associates</font>” if the providers or plans obtain satisfactory assurances that     the business <font color="blue">associate will use</font> the information only for the purposes for     which it was engaged by the covered entity, <font color="blue">will safeguard</font> the information     from  misuse, and will help the covered entity <font color="blue">comply with</font> some of the     covered  entity’s  duties  under  the  Privacy  Rule</td>
    </tr>
    <tr>
      <td>Covered entities     may disclose <font color="blue">protected health</font> information to an entity in its role as a     business associate only to help the covered entity carry out its <font color="blue">health care</font>     functions – not for the business associate’s independent use or purposes,     except  as  needed for the proper <font color="blue">management</font> and <font color="blue">administration</font> of the     business associate</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s are <font color="blue">necessary</font> for us in the normal     course of servicing and supporting our products</td>
    </tr>
    <tr>
      <td>If we are not willing to or     are unable to <font color="blue">enter into</font> a business associate <font color="blue">agreement</font> with current and     potential  customers,  <font color="blue">such customers may</font> not purchase our products or     services,  <font color="blue">which would</font> have a material adverse effect on our business,     <font color="blue">financial condition</font>, or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Uncertain Protection for Intellectual Property; Possible Claims of Others         Although we have received patents and have filed patent <font color="blue">applications</font> with     respect to <font color="blue">certain aspects</font> of our <font color="blue">technology</font>, we <font color="blue">generally</font> do not rely on     <font color="blue">patent protection with respect</font> to our products and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Instead, we     <font color="blue">rely primarily on</font> a <font color="blue">combination</font> of <font color="blue">trade secret</font> and copyright law, employee     and third-party non<font color="blue">disclosure</font> <font color="blue">agreement</font>s and other protective measures to     protect  <font color="blue">intellectual</font>  property  <font color="blue">rights pertaining</font> to our products and     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">measures may</font> not <font color="blue">provide meaningful protection</font> of our     <font color="blue">trade secret</font>s, know-how or other <font color="blue">intellectual</font> property in the event of any     unauthorized use, misappropriation or <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>Others <font color="blue">may independently</font>     develop similar <font color="blue">technologies</font> or duplicate our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>In addition, to     the extent that we apply for any patents, such <font color="blue">applications</font> may not result     in <font color="blue">issued patents</font> or, if issued, such patents may not be valid or of value</td>
    </tr>
    <tr>
      <td>We do not believe that our products and <font color="blue">technologies</font> infringe any existing     patents or <font color="blue">intellectual</font> <font color="blue">property rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>However, our     products and <font color="blue">technologies</font> may infringe existing patents or <font color="blue">intellectual</font>     <font color="blue">property rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>The costs of prosecuting or defending an     <font color="blue">intellectual</font> property claim could be substantial and <font color="blue">could <font color="blue">adversely</font> affect</font>     our  business,  even if we are <font color="blue">ultimately successful</font> in prosecuting or     defending any such claims</td>
    </tr>
    <tr>
      <td>If our products or <font color="blue">technologies</font> are found to     infringe  the  rights  of  a  <font color="blue">third party</font>, we could be required to pay     <font color="blue">significant</font> damages or <font color="blue">license fees</font> or <font color="blue">cease production</font>, any of <font color="blue">which could</font>     have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________         Product Liability Risk; Limited Insurance Coverage         The <font color="blue">manufacture</font> and sale of <font color="blue">products used</font> in the practice of <font color="blue">medicine entail</font>     <font color="blue">significant</font> risk of <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>We currently maintain product     <font color="blue"><font color="blue">liability</font> insurance</font> and <font color="blue">coverage limits</font> that we consider to be reasonable</td>
    </tr>
    <tr>
      <td>However, our <font color="blue">coverage limits</font> may not be adequate to <font color="blue">protect us from</font> any     <font color="blue">liabilities</font> we <font color="blue">might incur</font> in <font color="blue">connection with</font> claims in <font color="blue">connection with</font> our     products</td>
    </tr>
    <tr>
      <td>We may also need increased <font color="blue">product <font color="blue">liability</font></font> coverage as we     <font color="blue">release additional products</font> and updates</td>
    </tr>
    <tr>
      <td>Such insurance is expensive and     may not be <font color="blue">available on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>A <font color="blue">successful product</font>     <font color="blue">liability</font>  claim  or series of such claims <font color="blue">against us</font> in excess of our     <font color="blue">insurance coverage could</font> have a material adverse effect on our business,     <font color="blue">financial condition</font>, or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Need to Hire Additional Personnel         Our ability to enhance and develop markets for our <font color="blue">current products</font> and to     introduce <font color="blue">new products</font> to the <font color="blue">marketplace also depends on</font> our ability to     attract and retain <font color="blue">qualified scientific</font> and <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>We compete     for  such  personnel  with other companies, academic institutions, and     <font color="blue"><font color="blue">government</font> entities</font> and <font color="blue">organizations</font>, many of which have <font color="blue">greater capital</font>     resources, name recognition, and research and <font color="blue">development</font> capabilities</td>
    </tr>
    <tr>
      <td>There  can be no assurance that we will be successful in recruiting or     retaining <font color="blue">such personnel</font></td>
    </tr>
    <tr>
      <td>We may not be able to recruit and retain such     personnel, <font color="blue">which would</font> have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Management of Growth         Our  ability  to  <font color="blue">grow <font color="blue">successfully</font></font> requires an <font color="blue">effective</font> planning and     <font color="blue">management</font> process</td>
    </tr>
    <tr>
      <td>The expansion and growth of our business could place a     <font color="blue">significant</font> strain on our <font color="blue">management</font> systems, <font color="blue">infrastructure</font> and other     resources</td>
    </tr>
    <tr>
      <td>To <font color="blue">manage growth <font color="blue">successfully</font></font>, we <font color="blue">must continue</font> to improve and     expand our systems and <font color="blue">infrastructure</font> in a timely and <font color="blue">efficient manner</font></td>
    </tr>
    <tr>
      <td>In     addition,  the  success of any <font color="blue">acquisition</font>, such as our <font color="blue">acquisition</font> of     HInnovation, Inc</td>
    </tr>
    <tr>
      <td>in  <font color="blue">February </font>2004,  will  depend  on our ability to     <font color="blue">successfully</font>  integrate  the  acquired business with our business</td>
    </tr>
    <tr>
      <td>Our     controls, systems, procedures and <font color="blue">resources may</font> not be adequate to support a     changing and <font color="blue">growing company</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">management</font> fails to respond <font color="blue">effective</font>ly to     changes and growth in business, including <font color="blue">acquisition</font>s, such failure could     have a material adverse effect on our business, <font color="blue">financial condition</font>, or     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font>on Third-Party <font color="blue">Reimbursement </font>        Our products are purchased by hospitals, clinics, imaging centers and other     users, which bill various <font color="blue">third party</font> payers, such as <font color="blue">government</font> health     programs, private health insurance plans, managed care <font color="blue">organizations</font> and     other similar programs, for the <font color="blue">health care</font> goods and <font color="blue">services provided</font> to     their patients</td>
    </tr>
    <tr>
      <td>There are currently Current Procedural Terminology (CPT)     <font color="blue"><font color="blue">reimbursement</font> codes</font> for most of the <font color="blue">diagnostic procedures</font> that use our     products</td>
    </tr>
    <tr>
      <td>However, the amount of such <font color="blue">reimbursement</font> varies by location and     is subject to change</td>
    </tr>
    <tr>
      <td>Payers may deny <font color="blue">reimbursement</font> if they determine that a     <font color="blue">product used</font> in a procedure was not used in <font color="blue">accordance with established</font>     <font color="blue">payer protocol</font> regarding cost-<font color="blue">effective</font> treatment methods or was used for an     <font color="blue">unapproved indication</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">party payers</font> are increasingly challenging the     prices  charged  for <font color="blue">medical services</font> and, in some instances, have put     pressure  on  service  providers to lower their prices or reduce their     services</td>
    </tr>
    <tr>
      <td>Third party     payers  may not consider as cost <font color="blue">effective</font> the procedures in which our     products are used</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>for such procedures may not be available     or, if available, payers’ low <font color="blue">reimbursement</font> levels may <font color="blue">adversely</font> affect our     ability to sell our products on a profitable basis</td>
    </tr>
    <tr>
      <td>In addition, there have     been and <font color="blue">may continue</font> to be proposals by legislators, regulators and third     party  payers  to <font color="blue">curb further</font> these costs in the future</td>
    </tr>
    <tr>
      <td>A <font color="blue">failure by</font>     hospitals and other users of our products to obtain <font color="blue">reimbursement</font> from third     <font color="blue">party payers</font>, changes in <font color="blue">third party</font> payers’ policies toward <font color="blue">reimbursement</font>     for  procedures  using our products or <font color="blue">legislative action could</font> have a     material adverse effect on our business, <font color="blue">financial condition</font>, or results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Uncertainty of Health Care Reform         The levels of revenue and <font color="blue">profitability</font> of medical <font color="blue">technology</font> companies     may be <font color="blue">affected by</font> the efforts of <font color="blue">government</font> and <font color="blue">third party</font> payers to     contain or reduce the costs of <font color="blue">health care</font> through various means</td>
    </tr>
    <tr>
      <td>In the     United States, there have been, and we expect that there <font color="blue">will continue</font> to     be, a number of federal, state, and <font color="blue">private proposals</font> to control <font color="blue">health care</font>     costs</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">proposals may</font> contain measures intended</font> to <font color="blue">control public</font> and     private spending on <font color="blue">health care</font> as well as to <font color="blue">provide universal public</font>     access to the <font color="blue">health care</font> system</td>
    </tr>
    <tr>
      <td>If enacted, these <font color="blue">proposals may</font> result in     a substantial <font color="blue">restructuring</font> of the <font color="blue">health care</font> delivery system</td>
    </tr>
    <tr>
      <td><font color="blue">Significant     </font>changes in the nation’s <font color="blue">health care</font> system could have a substantial impact     on the manner in which we conduct business and could have a material adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________         Possible Issuances of Preferred Stock         Our <font color="blue">Articles of Incorporation </font>authorize our <font color="blue">Board of Directors</font>, without any     <font color="blue">action by</font> the holders of our <font color="blue">common stock</font>, to establish the rights and     <font color="blue">preferences</font> of up to 5cmam000cmam000 shares of <font color="blue">currently undesignated preferred</font>     stock</td>
    </tr>
    <tr>
      <td>These shares of <font color="blue"><font color="blue">preferred stock</font> could</font> possess voting and <font color="blue">conversion</font>     rights that <font color="blue">could <font color="blue">adversely</font> affect</font> the <font color="blue">voting power</font> of the holders of the     <font color="blue">common stock</font> or dilute their <font color="blue">ownership rights</font>, and it may have the effect of     delaying, deferring or preventing a change in control of Vital Images</td>
    </tr>
    <tr>
      <td>No     shares of <font color="blue">preferred stock</font> or other <font color="blue">senior equity securities</font> are currently     designated, and currently we have no plan to designate or issue any such     securities</td>
    </tr>
    <tr>
      <td>Anti-Takeover Considerations         We are subject to “anti-takeover” provisions of the <font color="blue">Minnesota </font>Business     Corporation Act</td>
    </tr>
    <tr>
      <td>In addition, we have adopted a <font color="blue">Shareholder Rights Plan </font>(the     “Rights Agreement”) designed to <font color="blue">protect against unsolicited attempts</font> to     acquire  Vital Images</td>
    </tr>
    <tr>
      <td>These <font color="blue">measures may</font> deter or <font color="blue">discourage takeover</font>     attempts and other changes in control that are not <font color="blue">approved by</font> our Board of     Directors, and they may have a <font color="blue">depressive</font> effect on any market for our     common  stock</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">shareholders</font> may lose <font color="blue">opportunities</font> to     dispose of their shares at the higher prices typically available in takeover     attempts or that may be available under a merger proposal</td>
    </tr>
    <tr>
      <td>In addition,     these <font color="blue">measures may</font> have the effect of permitting our <font color="blue">current <font color="blue">directors</font></font> to     retain their positions and place them in a <font color="blue">better position</font> to resist changes     that <font color="blue">shareholders</font> may wish to make if they are <font color="blue">dissatisfied with</font> the conduct     of our business</td>
    </tr>
    <tr>
      <td>No Dividends         We have not <font color="blue">paid cash dividends on</font> our <font color="blue">common stock</font> in the past, and we do     not intend to do so in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Any payment of <font color="blue">dividends will</font>     be in the <font color="blue">sole discretion</font> of our <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Limitations </font>on Director Liability         As <font color="blue">permitted by</font> <font color="blue">Minnesota </font>law, our <font color="blue">Articles of Incorporation </font>provide that     members of our board of <font color="blue">directors</font> shall not be <font color="blue">personally liable</font> to us or     our <font color="blue">shareholders</font> for <font color="blue">monetary damages</font> for breach of <font color="blue"><font color="blue">fiduciary</font> duty as</font> a     director,  with  certain  <font color="blue">exceptions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions may discourage</font>     <font color="blue">shareholders</font> from bringing suit against a director for breach of <font color="blue">fiduciary</font>     duty and may reduce the likelihood of <font color="blue">derivative litigation brought by</font>     <font color="blue">shareholders</font> on our <font color="blue">behalf against</font> a director</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">Bylaws     </font>provide for <font color="blue">mandatory indemnification</font> of <font color="blue">directors</font> and officers to the     fullest extent <font color="blue">permitted by</font> <font color="blue">Minnesota </font>law</td>
    </tr>
  </tbody>
</table>